Decision-Making Coherence in Market Access: Six Chapters Connecting Evidence, Value and Access
22 july 2026
Assessment does not create uncertainty. It makes it visible.
When Concorde was developed, the challenge was not simply to achieve an unprecedented speed. The real difficulty lay in ensuring that extraordinarily complex systems worked together in a coordinated way, transforming exceptional technical capability into a viable operation.
The same applies to Market Access.
Clinical evidence, health technology assessment, real-world data, economic impact, regulation, pricing and innovation are often developed within separate disciplines. Yet when a technology reaches the point of assessment, all those decisions ultimately converge in one place.
And it is precisely at that point that the strengths and tensions of an access strategy become visible.
We define decision-making coherence as a strategy’s ability to keep its different dimensions aligned when they converge during the assessment process.
This perspective underpins the Market Access editorial series developed by ProductLife Group through Outcomes’10 (A ProductLife Group Company).
To date, the first two series have explored six fundamental themes, ranging from the gap between evidence and decision-making to the need to adapt access strategies to an evolving assessment landscape.
Series 1: From Evidence to Decision
The first series examines why generating scientifically robust evidence does not, in itself, guarantee a favourable access decision.
- Why Doesn’t Having Data Always Lead to a PositiveMarketDecision?
What happens when the evidence is strong, yet the reimbursement decision is unfavourable? This first chapter explores the gap between the evidence generated and the way it is interpreted within real-world access processes.
- Assessment Processes and Strategic Uncertainty
Once a submission dossier has been filed, a phase begins that is not always fully transparent. This chapter explores how limited visibility can affect the ability to anticipate scenarios and refine strategy.
- Assessment Through the Decision-Maker’s Lens
Does the evidence address what decision-makers actually need to evaluate? The third chapter shifts perspective and examines what happens when the value proposition presented does not align with the priorities and criteria of the healthcare system.
Series 2: Adapting Strategy to a Changing Assessment Environment
The second series focuses on the evolution of assessment systems and the new demands this transformation places on Market Access strategies.
- The Evolution of Market Access
Assessment frameworks evolve, but not all access strategies evolve at the same pace. This chapter raises a challenging question: are access approaches designed for a previous environment still fit for purpose today?
- Digitalisation and Complexity in Assessment
Digitalisation brings greater structure, traceability and interaction to assessment processes. But does it actually make them simpler? This chapter explores how decision-making complexity changes as assessment models evolve.
- Innovation in Market Access
Why do some clinical and scientific innovations fail to translate into faster access? The latest chapter examines the gap between developing innovation and ensuring its relevance is recognised within real-world assessment pathways.
Four Conditions for Building Decision-Making Coherence
Drawing on the insights from these six chapters, we have identified four conditions that, in our experience, are particularly important for developing an access strategy that is both robust and assessment-ready.
- Assessment Relevance
Not all available evidence carries the same weight in decision-making. Its value depends on whether it addresses the questions raised by the assessment context: compared with what alternative, in which population, under what level of uncertainty, and with what implications for the healthcare system.
- Explicit Management of Uncertainty
Uncertainty is an inherent component of any assessment process. Strategic work does not consist of assuming it can be eliminated, but rather identifying where it resides, understanding how it may be interpreted, and evaluating which evidence or mechanisms can support its management.
- Translating Value
Innovation must be expressed in terms that can be assessed. This requires linking benefits to relevant comparators, meaningful outcomes, appropriate time horizons, and consequences that are understandable for patients, healthcare professionals and healthcare systems.
- Alignment Across Disciplines
Clinical evidence, HEOR, RWE, regulatory strategy and value positioning are often developed at different moments and by different teams. The risk emerges when each component is built on different assumptions or seeks to answer a different question.
These four conditions help determine whether a strategy can sustain a consistent interpretation of value throughout the assessment process.
The objective is not to standardise disciplines that fulfil distinct functions. Rather, it is to ensure that their conclusions reinforce one another instead of competing when they reach the assessment table.
A Conversation That Continues
These six chapters represent the first two series of a broader editorial journey.
Future publications will explore topics including uncertainty management, integration of multiple evidence sources, the relationship between regulation and access, healthcare system sustainability, and the ongoing evolution of assessment models.
This is where decisions are shaped.
And it is the landscape we will continue to explore.
Register to our news and events
Go to our Events to register
Go to our News to get insights
